For the six months ended June 30, net loss from continuing operations widened to USD 18.58 million, up 238%, including a USD 6.3 million non-cash goodwill impairment.
Cash and cash equivalents totaled USD 7.62 million at June 30; June registered direct offerings raised about USD 4.15 million in gross proceeds.
Quarterly loss widens as financing expenses surge
Nexentis reported a net loss from continuing operations of USD 11.16 million for the quarter ended June 30, 2026, widening 154% year over year.
Financing expenses, net climbed to USD 8.84 million, up 616%, driven by warrant-liability fair-value changes and day-one losses on June PIPE warrants.
General and administrative expense fell 52% to USD 1.26 million, while research and development expense was USD 373,000 following the October 2025 MitoCareX acquisition.
NXTS•
